Le Lézard
Classified in: Health
Subject: MRR

Pharmaceutical Excipients Market Worth $14.9 Billion | MarketsandMarkets


CHICAGO, Dec. 1, 2023 /PRNewswire/ -- Pharmaceutical Excipients Market in terms of revenue was estimated to be worth $10.7 billion in 2023 and is poised to reach $14.9 billion by 2028, growing at a CAGR of 6.8% from 2023 to 2028 according to a new report by MarketsandMarkets. The pharmaceutical excipients market is projected to grow at a CAGR of 6.8% during the forecast period of 2023 to 2028. The major factors attributing to the growth of the market are increasing demand for generic drugs and pharmaceutical products, increased R&D Investments for the development of novel excipients and growing emphasis on patient-centric formulations. Collaborations and partnerships with pharmaceutical companies for customized excipient solutions are likely to boost the growth of the market in the near future.

MarketsandMarkets_Logo

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=956

Browse in-depth TOC on "Pharmaceutical Excipients Market"

562 - Tables
51 - Figures
373 - Pages

Pharmaceutical Excipients Market Scope:

Report Coverage

Details

Market Revenue in 2023

$10.7 billion

Estimated Value by 2028

$14.9 billion

Growth Rate

Poised to grow at a CAGR of 6.8%

Market Size Available for

2021?2028

Forecast Period

2023?2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

By Product, By Functionality, By Formulation, By Functionality application

Geographies Covered

North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Increasing growth of functional/Multifunctional Pharmaceutical Excipients

Key Market Drivers

Increasing demand for generic drugs and pharmaceutical products is propelling the demand for pharma excipients

 

The organic chemicals segment dominated the market share in 2022 for the product segment.

Based on product, the global pharmaceutical excipients market is categorised into organic chemicals, inorganic chemicals and other chemicals. Organic chemicals are mainly chemicals with carbon atoms covalently linked to atoms of other elements. The non-toxic nature of organic chemicals is expected to drive the organic chemicals segments which in turn will uplift the pharmaceutical excipient market from 2023 to 2028.

Fillers and Diluents segment achieved top market share for the functionality segment in 2022

The fillers and diluents segment accounted for a majority of the market share in 2022. Fillers and diluents give form, bulk, or consistency to the product. The fillers and diluents market is expected to grow due to the rising use of fillers and diluents in developing and producing solid oral drugs. Tablets are the most popular dosage forms due to their advantages to manufacturers and patients and hence can drive the fillers and diluents market. The lubricants and glidants market is expected to grow at the fastest rate because they can improve the flow properties of a formulation by reducing the friction and cohesion between particles.

The Asia Pacific region predicted to showcase the most rapid growth during the forecast period.

The Asia Pacific region is poised to lead the market's expansion with the fastest market growth, driven by the low labor and manufacturing costs in China and India. These cost advantages have attracted significant investments from pharmaceutical giants to these countries. Additionally, the growing prevalence of lifestyle-related and age-related diseases, the rising disposable income, and government initiatives to improve healthcare infrastructure further contribute to the region's robust market growth.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=956

Pharmaceutical Excipients Market Dynamics:

Drivers:

  1. Increasing demand for generic drugs and pharmaceutical products is propelling the demand for pharma excipients

Restraints:

  1. High Development Costs associated with Novel excipients

Opportunities:

  1. Increasing growth of functional/Multifunctional Pharmaceutical Excipients

Challenge:

  1. Stringent Regulatory Requirements

Key Market Players of Pharmaceutical Excipients Industry:

The global pharmaceutical excipients market comprises of many key market players competing for markets shares like International Flavors & Fragrances Inc. (US), Ashland Inc. (US), Evonik Industries AG (Germany), BASF SE (Germany), Kerry Group Plc (Ireland), Roquette Frères (France), Merck KgaA (Germany), Associated British Foods Plc (UK), ADM (US), Wacker Chemie AG (Germany).

The primary interviews conducted for this report can be categorized as follows:

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=956

Pharmaceutical Excipients Market Recent Developments:

Pharmaceutical Excipients Market - Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical excipients market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Related Reports:

Autoinjectors Market - Global Forecasts to 2028

Active Pharmaceutical Ingredient Market - Global Forecasts to 2027

High Potency APIs Market - Global Forecasts to 2027

Pharmaceutical Drug Delivery Market - Global Forecasts to 2026

Wearable Injectors Market - Global Forecasts to 2026

About MarketsandMarketstm:

MarketsandMarketstm has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarketstm is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStoretm (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarketstm.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarketstm INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/pharma-excipients-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/pharma-excipients.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

 

SOURCE MarketsandMarkets


These press releases may also interest you

at 04:00
Launched in 2020, Tali AI has a clear goal: to revolutionize healthcare delivery and reduce clinician burnout by lifting the administrative burden and enabling clinicians to focus on the patient rather than the computer screen. Tali AI, co-designed...

at 04:00
Affidea Group, Europe's largest provider of advanced diagnostics, multi-speciality polyclinics and Centres of Excellence, announced today that it has entered into a binding agreement to acquire MedEuropa Romania, a renowned cancer care provider....

at 03:59
Medivir AB , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Life Science Day in Gothenburg on March 6, 2024. CEO Jens Lindberg...

at 03:36
The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and...

at 03:30
Samyang Group announced that KCI (CEO Jinyong Lee), a subsidiary specializing in cosmetics and personal care materials, won 'Platinum Medal', the highest grade, in the 2024 Sustainability Rating from 'EcoVadis', a global ESG rating agency....

at 03:00
Insightec, a pioneer and global leader in focused ultrasound, is pleased to announce that its transcranial MR-guided focused ultrasound (MRgFUS) has been granted NUB status 1 for the treatment of essential tremor (ET) in Germany. This significant...



News published on and distributed by: